Trial · NCT03430180
Effects of Intranasal Naloxone on Gambling Urges and Craving in Gambling Disorder
NCT03430180, Phase 2, Unknown, Finnish Institute for Health and Welfare
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effects of Intranasal Naloxone on Gambling Urges and Craving in Gambling Disorder. Trials, record NCT03430180. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03430180
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effects of Intranasal Naloxone on Gambling Urges and Craving in Gambling Disorder
- NCT number
- NCT03430180
- Status
- Unknown
- Phases
- Phase 2
- Enrollment
- 126 participants, estimated
- Lead sponsor
- Finnish Institute for Health and Welfare
- Conditions
- Pathological Gambling, Gambling Disorder, Opioid Antagonist, Naloxone
- Interventions
- Naloxone hydrochloride, Placebo
- First posted
- 2018-02-12
- Last updated
- 2019-07-16
- Other registries' IDs
- eudract:2017-001946-93
Source ClinicalTrials.gov
Registered outcomes18
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | The Gambling Symptom Assessment Scale (G-SAS) gambling symptom severity and change during the treatment - assessment | Baseline to week, 3, 6, 9 and week 12. | The G-SAS is a 12-item self-rated scale designed to assess gambling symptom severity and change during treatment. The G-SAS is not a diagnostic or screening instrument. Each 12-item scale has a score ranging from 0 - 4 (adjective anchors for 0 and 4 vary for each item). All items ask for an average symptom based on the past 7 days. Items 1 - 4 can be used to assess changes in craving symptoms. Total score ranges from 0 - 48: extreme = 41 - 48, severe = 31 - 40, moderate = 21 - 30, mild = 8 - 20. |
| Secondary | VAS (gambling craving) | Baseline to Week 3, 6, 9 and 12 | The entire study for an individual participant will last 12 weeks. From baseline to weeks 3,6,9,and 12 craving of gambling will be assessed. |
| Secondary | Gambling severity (PGSI) | Baseline to Week 6 and 12 | The entire study for an individual participant will last 12 weeks. From baseline to weeks 6, and 12 severity of gambling will be assessed. |
| Secondary | Gambling severity (DSM-5) | Baseline to Week 6 and 12 | The entire study for an individual participant will last 12 weeks. From baseline to week 6, and 12 severity of gambling will be assessed. |
| Secondary | Gambling problems (NODS) | Baseline to Week 3, 6, 9 and 12 | The entire study for an individual participant will last 12 weeks. From baseline to weeks 3,6,9,and 12 level of gambling problems will be assessed. |
| Secondary | Gambling expenditure and frequency | Baseline to Week 12 | daily questionnaire / telephone operated (text messages) diary (daily use of sprays, number of doses, gambling expenditure and frequency and possible adverse events) and self-administration of IMP. |
| Secondary | Abstinence of gambling (GASS) | Baseline to Week 3, 6, 9 and 12 | The entire study for an individual participant will last 12 weeks. From baseline to weeks 3,6,9,and 12 abstinence of gambling will be assessed. |
| Secondary | Internet use (Internet disorder scale-9 short form) | Baseline to Week 6 and 12 | The entire study for an individual participant will last 12 weeks. From baseline to weeks 6, and 12 internet use will be assessed. |
| Secondary | Quality of life (WHO: EUROHIS-8) | Baseline to Week 6 and 12 | The entire study for an individual participant will last 12 weeks. From baseline to weeks 6, and 12 quality of life will be assessed. |
| Secondary | Alcohol consumption (AUDIT) | Baseline to Week 6 and 12 | The entire study for an individual participant will last 12 weeks. From baseline to weeks 6, and 12 graving of gambling will be assessed. |
1 to 10 of 18Source ClinicalTrials.gov
See all 18 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03430180
GET https://conductscience.org/api/trials/v1/NCT03430180/registered